Utilization of HCV Viremic Kidneys with Genotyping/Subtyping-Free Sofosbuvir/Velpatasvir Treatment Strategy: Experience from China

BACKGROUND: Owing to the advent of pangenotypic direct-acting antiviral agents (DAAs) for hepatitis C virus (HCV) treatment, utilization of HCV-infected deceased donor kidneys with simplified genotyping/subtyping-free sofosbuvir/velpatasvir (SOF/VEL) treatment strategy is now becoming a promising st...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Hedong, Liu, Qiuhao, Hu, Shanbiao, Zhong, Mingda, Peng, Fenghua, Guo, Yong, Fang, Chunhua, Nie, Manhua, Tan, Liang, Dai, Helong, Xie, Xubiao, Peng, Longkai, Lan, Gongbin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9356870/
https://www.ncbi.nlm.nih.gov/pubmed/35941983
http://dx.doi.org/10.1155/2022/3758744

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9356870/
https://www.ncbi.nlm.nih.gov/pubmed/35941983
http://dx.doi.org/10.1155/2022/3758744

Ejemplares similares